BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...WorldMeds LLC, including marketed drugs Myobloc rimabotulinumtoxinB for cervical dystonia and chronic sialorrhea and Apokyn apomorphine hydrochloride...
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

...Inside Japan KHK launched two new products in Japan in 2012: Poteligeo and Parkinson's drug Apokyn...
...colorectal cancer . In CNS, KHK wants to expand products for PD and quickly launch Apokyn...
BioCentury | Dec 3, 2012
Clinical News

APL-130277: Phase I started

...Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine hydrochloride...
BioCentury | Aug 6, 2012
Company News

Kyowa Hakko Kirin sales and marketing update

...Parkinson's disease (PD). Apokyn has Orphan Drug status in Japan. Kyowa has rights to the apomorphine hydrochloride...
...Pharmaceutical Ltd. subsidiary of Stada Arzneimittel AG (Xetra:SAZ, Bad Vilbel, Germany) under a 2006 deal. Apokyn...
BioCentury | May 7, 2012
Finance

BG-12 deal keeps on giving

...dropped 5% to €16.4M ($21.9M) due to the sale of marketing rights for neurology drug Apokyn...
BioCentury | Apr 9, 2012
Clinical News

Apokyn apomorphine hydrochloride regulatory update

...Parkinson's disease (PD). Apokyn has Orphan Drug designation in Japan. Kyowa has rights to the apomorphine hydrochloride...
...Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Stada Arzneimittel AG (Xetra:SAZ), Bad Vilbel, Germany Product: Apokyn apomorphine hydrochloride...
BioCentury | Jan 16, 2012
Clinical News

APL-130277: Phase I data

...Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine hydrochloride...
BioCentury | Dec 19, 2011
Company News

Ipsen, Vernalis deal

...deal in which Ipsen acquired Vernalis' U.S. commercial operations subsidiary and U.S. rights to Vernalis' Apokyn...
...deal, the final milestone payment was to be triggered by combined net annual sales of Apokyn...
...American commercialization rights for Apokyn to treat "off" episodes associated with Parkinson's disease (PD). The apomorphine hydrochloride...
BioCentury | Nov 7, 2011
Company News

Britannia, Ipsen sales and marketing update

...Britannia acquired North American commercialization rights from Ipsen for Apokyn apomorphine to treat "off" episodes associated...
...the deal. Apokyn's 2010 sales were $7.9 million. Ipsen has North American rights to the apomorphine hydrochloride...
BioCentury | Mar 8, 2010
Finance

EPS Watch

...€255.3M ($367.9M), up 8.2% from €235.9M. Sales for the company's specialist care business, which includes Apokyn...
Items per page:
1 - 10 of 28